NCT05734495View on ClinicalTrials.gov

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 2, 2023

Primary Completion Date

January 25, 2029

Study Completion Date

January 25, 2033

Conditions
Waldenstrom Macroglobulinemia
Interventions
DRUG

Pirtobrutinib

Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor, tablet taken orally.

DRUG

Venetoclax

Small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor, tablet taken orally.

Trial Locations (2)

02215

RECRUITING

Beth Israel Deaconness Medical, Boston

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER